Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Nab-paclitaxel + Toripalimab-tpzi
Indication/Tumor Type triple-receptor negative breast cancer
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive triple-receptor negative breast cancer predicted - sensitive Nab-paclitaxel + Toripalimab-tpzi Phase III Actionable In a Phase III trial (TORCHLIGHT), treatment with Loqtorz (toripalimab-tpzi) plus Abraxane (nab-paclitaxel) demonstrated safety and led to an improved median progression-free survival (mPFS) compared to nab-paclitaxel plus placebo in CD274 (PD-L1)-positive (CPS >/= 1) triple-negative breast cancer patients, with a mPFS of 8.4 vs 5.6 mo (HR=0.65, p=0.0102) and in the intention to treat population, a mPFS of 8.4 vs 6.9 mo (PMID: 38191615; NCT03777579, NCT04085276). 38191615
PubMed Id Reference Title Details
(38191615) Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Full reference...